Private Management Group Inc. Decreases Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Private Management Group Inc. lessened its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 7.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,273,997 shares of the company's stock after selling 101,434 shares during the period. Private Management Group Inc. owned approximately 0.11% of Teva Pharmaceutical Industries worth $22,957,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. New Covenant Trust Company N.A. purchased a new stake in Teva Pharmaceutical Industries during the 1st quarter worth approximately $28,000. EntryPoint Capital LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at $30,000. UMB Bank n.a. increased its position in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock valued at $44,000 after acquiring an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA purchased a new position in Teva Pharmaceutical Industries in the 2nd quarter worth $48,000. Finally, Byrne Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries during the 2nd quarter worth about $52,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. UBS Group raised their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a "buy" rating in a research note on Tuesday, September 3rd. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 23rd. Argus upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and set a $20.00 target price for the company in a research report on Wednesday, July 10th. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, October 21st. Finally, StockNews.com raised Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $19.67.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA traded up $0.01 during trading on Friday, reaching $18.45. 7,100,136 shares of the company's stock traded hands, compared to its average volume of 5,049,047. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 2.52. Teva Pharmaceutical Industries Limited has a fifty-two week low of $8.55 and a fifty-two week high of $19.08. The company has a 50-day simple moving average of $18.02 and a 200-day simple moving average of $16.95. The firm has a market cap of $20.90 billion, a PE ratio of -47.31, a P/E/G ratio of 1.33 and a beta of 0.87.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.58 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.03. Teva Pharmaceutical Industries had a positive return on equity of 39.66% and a negative net margin of 2.73%. The business had revenue of $4.16 billion during the quarter, compared to analysts' expectations of $3.99 billion. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.33 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.